Caris Life Sciences, Inc.(CAI)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,290 of 2,879 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
CAI Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Caris Life Sciences, Inc. (CAI), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CAI at 32.0/100 on a 32-signal composite quality model, placing it at rank #2,290 of 2,879 stocks — the bottom half of the AI-ranked universe. CAI scores in the top quartile across institutional flow (83.4). Areas of concern include revenue growth (29.5) and profitability (30.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 18.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Caris Life Sciences, Inc. reports quarterly revenue of $216.2M, net income of $-510.0K, an operating margin of 2.4%. Top institutional holders of CAI by reported 13-F value include FMR, J. H. Whitney Equity Partners VI,, Sixth Street Partners Management Company, L.P., based on the most recent SEC filings. CAI trades on the Nasdaq exchange and files with the SEC under CIK 2019410. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CAI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Caris Life Sciences, Inc. directly from SEC EDGAR.
Revenue
Q1 2026
$216.2M
Net Income
Q1 2026
$-510.0K
Free Cash Flow
Q1 2026
$22.5M
Operating Margin
Q1 2026
2.4%
ROIC
Q1 2026
0.5%
D/E Ratio
Q1 2026
0.64
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
+97.0% YoYNet Income
+75.8% YoYOperating Income
+117.5% YoYEPS (Diluted)
+69.8% YoYTotal Assets
+227.5% YoYTotal Debt
-12.5% YoYOp. Cash Flow
+133.9% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Revenue | $812.0M +97.0% | $412.3M +34.7% | $306.1M | — |
| Net Income | $-68.1M +75.8% | $-281.9M +17.4% | $-341.4M | — |
| Operating Income | $45.1M +117.5% | $-257.1M +19.5% | $-319.6M | — |
| EPS (Diluted) | $-3.22 +69.8% | $-10.66 +19.5% | $-13.24 | — |
| Total Assets | $1.13B +227.5% | $343.7M | — | — |
| Total Debt | $379.0M -12.5% | $433.2M | — | — |
| Operating Cash Flow | $83.2M +133.9% | $-245.2M +11.2% | $-276.1M | — |
AI Insight: CAI Financial Trends
Caris Life Sciences posted a sharp sequential earnings reversal in Q1 2026, swinging from $82M net income in Q4 2025 to a $1M net loss despite stable revenue.
• Operating income collapsed from $88M in Q4 2025 to $5M in Q1 2026, a drop of $83M quarter-over-quarter.
• Revenue was flat at $216–$217M in Q3 2025 and Q1 2026, with Q4 2025 an outlier spike to $293M.
• Equity has grown steadily from $453M in Q2 2025 to $593M in Q1 2026, reflecting cumulative earnings retention.
• Operating cash flow declined from $62M in Q3 2025 to $33M in Q1 2026, tracking the earnings softness.
⚠ Q4 2025 revenue of $293M appears anomalous; confirm whether it reflects seasonality or a one-time event.
⚠ Total debt crept up from $374M in Q2 2025 to $382M in Q1 2026 while profitability deteriorated — leverage trending modestly higher.
⚠ Only three quarters of income-statement data available; trends remain difficult to assess with confidence.
AI Insight: CAI Ratio Trends
Q4 2025's exceptional 30.2% operating margin collapsed to 2.4% in Q1 2026, raising questions about earnings quality and seasonality.
• Operating margin swung from 30.2% in Q4 2025 to just 2.4% in Q1 2026 — a 27.8pp sequential drop.
• ROIC cratered from 37.0% in Q4 2025 to 2.2% in Q1 2026, reflecting near-zero profitability in the latest quarter.
• D/E ratio has declined steadily from 0.83 in Q2 2025 to 0.64 in the TTM period, indicating gradual deleveraging.
⚠ Net profit margin turned slightly negative (-0.2%) in Q1 2026 after reaching 28.0% in Q4 2025 — watch for one-off drivers.
⚠ Only three quarters of profitability data exist; insufficient history to distinguish seasonal patterns from structural deterioration.
Get alerted when CAI's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Caris Life Sciences, Inc. including:
Top Institutional Holders of CAI
FMR LLC
$550.4M30,785,585 shJ. H. Whitney Equity Partners VI, LLC
$326.4M18,256,615 shSixth Street Partners Management Company, L.P.
$257.2M14,385,399 shCOATUE MANAGEMENT LLC
$175.6M9,819,992 shBRAIDWELL LP
$143.2M8,009,447 shPointState Capital LP
$131.6M7,360,446 shBlackRock, Inc.
$86.8M4,857,112 shVANGUARD PORTFOLIO MANAGEMENT LLC
$67.2M3,758,462 shNeuberger Berman Group LLC
$64.2M3,590,586 shVANGUARD CAPITAL MANAGEMENT LLC
$59.5M3,329,021 sh
| Fund | Value | Shares |
|---|---|---|
| FMR LLC | $550.4M | 30,785,585 |
| J. H. Whitney Equity Partners VI, LLC | $326.4M | 18,256,615 |
| Sixth Street Partners Management Company, L.P. | $257.2M | 14,385,399 |
| COATUE MANAGEMENT LLC | $175.6M | 9,819,992 |
| BRAIDWELL LP | $143.2M | 8,009,447 |
| PointState Capital LP | $131.6M | 7,360,446 |
| BlackRock, Inc. | $86.8M | 4,857,112 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $67.2M | 3,758,462 |
| Neuberger Berman Group LLC | $64.2M | 3,590,586 |
| VANGUARD CAPITAL MANAGEMENT LLC | $59.5M | 3,329,021 |
More Healthcare Companies
View all Healthcare →Put CAI on your watchlist
Track score changes the day Caris Life Sciences, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is CAI a good stock to buy?
13F Pro's AI-powered analysis of Caris Life Sciences, Inc. (CAI) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CAI are available on the CAI stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own CAI?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CAI. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Caris Life Sciences, Inc.'s investment landscape.